SLC5A2 and diabetes mellitus: Some SGLT2 inhibitors have also been shown to reduce heart failure in patients with diabetes or heart failure, death, and renal outcomes and some GLP-1 agonists have been shown to reduce the risk of all-cause mortality and improve renal outcomes [40, 46–48].